Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/877
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTan, Nicole-
dc.contributor.authorDick, Ronald-
dc.contributor.authorMarasco, Silvana-
dc.contributor.authorDuffy, Stephen-
dc.contributor.authorStub, Dion-
dc.contributor.authorWalton, Anthony-
dc.date.accessioned2016-11-11T01:18:42Z-
dc.date.available2016-11-11T01:18:42Z-
dc.date.issued2016-07-
dc.identifier.citationPoster 44en_US
dc.identifier.urihttp://hdl.handle.net/11434/877-
dc.description.abstractTranscatheter Aortic Valve Implantation (TAVI) is a minimally invasive procedure used to treat patients with symptomatic aortic stenosis. One of complications of TAVI is cardiac conduction abnormalities which requires permanent pacemaker insertion (PPI). This study determined the rate and contributing factors leading to PPI in patients after TAVI procedure. Method: We retrospectively analysed 196 patients that underwent elective TAVI from March 2010 to March 2016 at Epworth hospital. Eighteen patients with pre-operative pacemakers were excluded from the study leaving 178 patients for subsequent analysis. Statistical analysis was performed with MedCalc and GraphPad software. Results: The mean age of 178 TAVI patients was 84.4 ± 5.2 years with 46% male patients. The Core Vale prosthesis (CVP) was used in 154 patients whereas 24 patients received the Evolut R prosthesis (ERP). The mean Society of Thoracic Surgeons' (STS) risk score for all patients was 5.1±3.1. A total of 53 (30%) patients suffered from cardiac arrhythmias requiring PPI post-TAVI. The average timeframe for PPI was 3.1±5.0 days post-TAVI with 89% occurring within a week. Atroventricular (AV) block accounted or 68% of cases and majority of the AV blocks documented were complete hart blocks. PPI was increased with the use of CVP (33%) as compared to ERP (13%) (P=0.08, RR 046, 95%CI 0.1‛a1.1). The risk also increased with larger prosthetic valves (P=0.01, 95%CI - 3.6‛a-1.3) and deeper valve deployment into the aortic annulus (P=0.0001, 95%CI - 3.6a‛-1.3).en_US
dc.subjectPoster 44en_US
dc.subjectAnaestheticen_US
dc.subjectAortic Valveen_US
dc.subjectTAVIen_US
dc.subjectAortic Stenosisen_US
dc.subjectCardiac Conduction Abnormalitiesen_US
dc.subjectPermanent Pacemaker Insertionen_US
dc.subjectPPIen_US
dc.subjectAtroventricular (AV) Blocken_US
dc.subjectPacemakersen_US
dc.subjectTranscatheter Aortic Valve Implantationen_US
dc.subjectTAVIen_US
dc.subjectCore Vale prosthesisen_US
dc.subjectCVPen_US
dc.subjectSociety of Thoracic Surgeonsen_US
dc.subjectSTSen_US
dc.subjectCritical Care Clinical Institute, Epworth HealthCare, Victoria, Australiaen_US
dc.subjectCardiac Sciences Clinical Institute, Epworth HealthCare, Victoria, Australiaen_US
dc.titlePermanent pacemaker insertion after transcatheter aortic valve implantation.en_US
dc.typeConference Posteren_US
dc.description.affiliatesMonash Universityen_US
dc.type.studyortrialCohort Studyen_US
dc.description.conferencenameResearch Week 2016en_US
dc.description.conferencelocationEpworth Research Institute, Epworth Health Care, Richmond, Victoria, Australia.en_US
dc.type.contenttypeTexten_US
Appears in Collections:Cardiac Sciences
Critical Care
Research Week

Files in This Item:
There are no files associated with this item.


Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.